@article{ref1,
title="Insomnia and suicide as reported adverse effects of second-generation antipsychotics and mood stabilizers",
journal="Journal of clinical sleep medicine",
year="2021",
author="Miller, Brian J. and McCall, William V.",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="STUDY OBJECTIVES: Insomnia and suicide ideation/behavior/death (SIB) are common in psychiatric disorders. There is evidence that clozapine and lithium have anti-suicidal properties and beneficial effects on sleep. We investigated the reported odds of spontaneously reported psychiatric adverse drug reactions (ADRs) of insomnia and SIB in adults for second-generation antipsychotics (SGAs) and mood stabilizers compared to clozapine and lithium, respectively. <br><br>METHODS: We searched the U.S. FDA Adverse Event Reporting System from inception through February 2021 for which a SGA or mood stabilizer was the suspected agent of a psychiatric ADR. <br><br>RESULTS: We investigated 10 SGAs and 5 mood stabilizers. Compared to clozapine, other SGAs were associated with a significantly increased reported odds of insomnia (rOR=2.41-9.70) and SIB (rOR=1.18-2.72). Compared to lithium, there was a significantly increased reported odds of SIB (rOR=1.17-1.70) for other mood stabilizers, and insomnia (rOR=1.66) for lamotrigine. The insomnia and SIB rORs for SGAs and mood stabilizers were positively correlated. <br><br>CONCLUSIONS: Our results are consistent with evidence for anti-suicidal properties of clozapine and lithium. <br><br>FINDINGS also raise the possibility of beneficial effects on sleep as one potential pathway underlying the anti-suicidal properties for these agents. Future studies are needed to identify underlying biological mechanisms that contribute to these associations.<p /> <p>Language: en</p>",
language="en",
issn="1550-9389",
doi="10.5664/jcsm.9646",
url="http://dx.doi.org/10.5664/jcsm.9646"
}